募集资金使用情况

Search documents
微芯生物: 毕马威华振会计师事务所关于深圳微芯生物科技股份有限公司前次募集资金使用情况报告的鉴证报告
Zheng Quan Zhi Xing· 2025-08-14 16:15
Core Viewpoint - The report provides a verification of the usage of funds raised by Shenzhen Micron Biotech Co., Ltd. through the issuance of convertible bonds, confirming that the funds have been used in accordance with regulatory guidelines and accurately reflect the company's financial activities as of March 31, 2025 [1][2][3]. Fundraising and Storage - The company raised a total of RMB 500 million by issuing 5 million convertible bonds at a face value of RMB 100 each, with all funds received by July 11, 2022 [2]. - As of March 31, 2025, the total amount stored in designated accounts was RMB 484,537,300.00 [2]. Fund Usage - The report details the usage of the raised funds, with a total of RMB 356,400,958.33 utilized by March 31, 2025 [5]. - The company has made adjustments to the investment projects funded by the raised capital, specifically reallocating funds to meet market demands for a new drug, Seglitazone [3][4]. Changes in Fund Allocation - The company approved a proposal to change the use of part of the funds originally allocated for the production of CS12192 to instead support the production of Seglitazone [3]. - The total amount of funds that were reallocated was RMB 20,592,700.00 [5]. Cash Management of Idle Funds - The company has been authorized to use up to RMB 300 million of temporarily idle funds for cash management, ensuring that this does not affect the ongoing investment plans [4]. - The cash management strategy includes investing in safe, liquid, and guaranteed return products, with a maximum investment period of 12 months [4]. Remaining and Surplus Funds - As of March 31, 2025, there were no surplus funds remaining from the previous fundraising activities [5]. Project Benefits - The report includes an assessment of the benefits realized from the investment projects funded by the raised capital, although some projects are still in progress and have not yet reached their expected operational status [5].
法尔胜: 第十一届监事会第十次会议决议公告
Zheng Quan Zhi Xing· 2025-08-14 11:11
Group 1 - The supervisory board of Jiangsu Farsen Co., Ltd. held a meeting on August 8, 2025, to discuss and approve several key matters, including the revision of the 2025 stock issuance plan due to a transfer of shares among its controlling shareholders [1][2] - The independent directors of the company also approved the revised stock issuance plan, with a unanimous vote of 5 in favor, 0 against, and 0 abstentions [2] - The company engaged Zhongxinghua Accounting Firm to audit its internal control and issued a report on the internal control evaluation for the first quarter of 2025, which was also approved by the audit committee with the same voting results [2][3] Group 2 - The company prepared a report on the use of previously raised funds, which was verified by Zhongxinghua Accounting Firm, and the independent directors approved this report with a unanimous vote [3] - The details of the revised stock issuance plan and the previous fundraising usage report were disclosed on the company's official website [1][3]
顺博合金: 众会字(2025)第09874号前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-07-22 16:27
Core Viewpoint - The report provides a verification of the use of previously raised funds by Chongqing Shunbo Aluminum Alloy Co., Ltd., confirming that the funds have been utilized in accordance with the regulations set by the China Securities Regulatory Commission [2][6]. Fundraising and Storage Situation - The company raised a net amount of RMB 413,079,107.54 from its initial public offering on August 19, 2020, after deducting issuance costs of RMB 32,650,892.46 [3]. - As of June 30, 2025, the company has used all the raised funds, and the special account for these funds has been closed [3][10]. Actual Use of Funds - The report details the actual use of funds from the initial public offering, convertible bonds, and private placements, with specific amounts allocated to various projects [6][11]. - The total amount raised from the issuance of convertible bonds was RMB 818,950,877.36, after deducting issuance costs [3]. Changes in Fund Use - There have been no changes in the use of funds from the initial public offering, convertible bonds, or private placements as of June 30, 2025 [6]. Investment Project Transfer and Replacement - The company has replaced RMB 14,160.91 million of its own funds that were initially invested in projects with the raised funds, confirming the replacement through verification reports [6][7]. Effectiveness of Investment Projects - The effectiveness of investment projects funded by the raised capital is detailed in the report, showing varying degrees of success in achieving expected benefits [11][12]. Idle Fund Usage - The company temporarily supplemented working capital with idle funds amounting to RMB 25,175,300, which was fully returned to the special account within the stipulated time [9][10]. - Over RMB 440 million of idle funds were used to purchase low-risk financial products, generating a total return of RMB 208.05 million [10]. Remaining Funds and Usage - As of June 30, 2025, the company has fully utilized the previously raised funds, with a remaining balance of RMB 13,140,852.11 in the special account, which is earmarked for future project payments [10][12].
威力传动: 天健会计师事务所(特殊普通合伙)关于银川威力传动技术股份有限公司前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-07-17 12:16
Core Viewpoint - The report provides an overview of the usage of previously raised funds by Yinchuan Weili Transmission Technology Co., Ltd. as of March 31, 2025, confirming compliance with regulatory guidelines and detailing the financial activities related to the funds raised through the company's public offering [1][2][3]. Fundraising and Storage - The company raised a total of RMB 640.78 million by issuing 18.096 million shares at RMB 35.41 per share, with net proceeds amounting to RMB 582.72 million after deducting underwriting and other fees [3][4]. - As of March 31, 2025, the funds were stored in various bank accounts, with a total of RMB 582.72 million available [6][8]. Fund Usage - The total amount of funds used was RMB 479.62 million, with no changes in the intended use of the funds reported [6][8]. - The actual investment in the precision wind power reducer production project was RMB 479.62 million, which was lower than the committed investment of RMB 555.04 million, resulting in a shortfall of RMB 75.41 million [7][8]. Project Performance - The precision wind power reducer production project has not met its expected returns, with cumulative returns falling below the promised level by over 20%, attributed to market conditions and longer delivery cycles [7][8]. - The company has not utilized any idle funds, and all surplus funds have been redirected to enhance working capital for core business operations [8][9]. Conclusion - The report concludes that the management's report on the usage of previously raised funds accurately reflects the company's financial activities and complies with the relevant regulatory requirements [2][3].
风神股份: 风神轮胎股份有限公司截至2025年3月31日止前次募集资金使用情况报告的公告
Zheng Quan Zhi Xing· 2025-07-16 10:19
Summary of Key Points Core Viewpoint - The report details the usage of funds raised by Windshun Tire Co., Ltd. through a non-public offering, confirming that all funds have been utilized as planned without any changes to investment projects or temporary idle funds [1]. Group 1: Fundraising Overview - The company raised a total of RMB 625,965,899.02 through the issuance of 168,723,962 shares at a price of RMB 3.71 per share, with a net amount of RMB 622,451,776.78 after deducting issuance costs [1]. - As of March 31, 2025, the balance of the raised funds is reported as zero [1]. Group 2: Fund Utilization - The actual usage of the raised funds totaled RMB 62,245.18 million, with no changes in the investment projects [1]. - The company approved the use of RMB 46 million of the raised funds to replace self-raised funds that were previously invested in the projects [1]. Group 3: Economic Benefits - The report indicates that certain projects funded by the raised capital do not generate direct economic benefits and cannot be individually accounted for [1]. - There is no applicable difference between the cumulative realized benefits from the investment projects and the promised cumulative benefits [1]. Group 4: Asset Operation - There are no instances of using the raised funds for acquiring shares in assets [1]. Group 5: Approval and Reporting - The report was approved by the board of directors on July 16, 2025 [1].
智明达: 成都智明达2025年第二次临时股东会会议材料
Zheng Quan Zhi Xing· 2025-07-07 16:14
Group 1 - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including stock issuance and dividend plans [1][2][8] - The meeting will take place on July 16, 2025, at 15:00, with both on-site and online voting options available [7][5] - The company emphasizes the importance of maintaining order and protecting shareholder rights during the meeting [2][3] Group 2 - Proposal one involves issuing stocks through a simplified procedure, with a focus on the potential dilution of immediate returns for existing shareholders and measures to compensate for this dilution [6][8] - Proposal two outlines the company's dividend return plan for the next three years (2025-2027), aimed at enhancing transparency and operational feasibility in profit distribution [8][9] - Proposal three presents a report on the usage of previously raised funds, which has been verified by an accounting firm [9][10]
宁波华翔: 前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-06-13 13:20
Group 1 - The report is a verification of the usage of funds raised by Ningbo Huaxiang Electronics Co., Ltd. as of March 31, 2025, prepared by the management [1][3] - The report is intended solely for the issuance of stocks to specific parties and cannot be used for any other purpose [1] - The management is responsible for providing accurate and complete information in accordance with the regulations set by the China Securities Regulatory Commission [2] Group 2 - The total amount raised from the non-public offering was RMB 1,617.55 million, with a net amount of RMB 1,609.69 million after deducting fees [3][4] - As of March 31, 2025, all raised funds have been fully utilized, and the special account for these funds has a balance of RMB 0 [4] - The verification of the fund usage was conducted by Tianjian Accounting Firm, confirming compliance with regulatory guidelines [3][4]
沃格光电: 江西沃格光电集团股份有限公司前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-05-30 10:41
Summary of Key Points Core Viewpoint - The report provides an overview of the fundraising activities and the usage of funds by Jiangxi Woge Optoelectronics Group Co., Ltd. as of March 31, 2025, confirming compliance with regulatory requirements and reflecting the actual usage of previously raised funds [1][3]. Fundraising and Storage - The company raised a total of RMB 170.50 million through a non-public offering of 14,800,347 shares at RMB 11.52 per share, with net proceeds amounting to RMB 166.77 million after deducting underwriting and sponsorship fees [3][4]. - As of March 31, 2025, the total amount of funds stored in the bank account was RMB 167.70 million, with a noted difference of RMB 1.58 million due to deducted fees [5][6]. Fund Usage - The actual investment amount from the raised funds was RMB 166.13 million, which is RMB 1.53 million more than the committed investment amount, attributed to interest income and net fees [6][7]. - The funds were primarily used to supplement working capital and repay bank loans, enhancing the company's operational capacity and risk management, but did not generate direct measurable benefits [6][7]. Fund Management - There were no instances of idle funds being used for cash management as of the reporting date [7]. - The company did not engage in any transfer or replacement of investment projects funded by the previous fundraising [6][7].
兴齐眼药: 前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-05-27 11:24
Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Shenyang Xingqi Eye Pharmaceutical Co., Ltd. as of December 31, 2024, highlighting the financial figures and project statuses [1][2][3]. Fundraising Overview - The company raised a total of RMB 599,669,492.10 through the issuance of 5,763,282 shares, with actual funds received amounting to RMB 581,870,425.73 after deducting underwriting fees [1][2]. - The funds were fully received by December 22, 2021, and verified by a certified public accountant [1]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 382,520,531.09, with remaining funds of RMB 195,077,792.24 held in a dedicated bank account [2][3]. - The company has not changed the investment projects but adjusted the implementation locations for certain projects, specifically the "R&D Center Construction" project [2][3]. Project Status and Economic Benefits - The "Single-Dose Production Line Construction" project is expected to achieve an internal rate of return of 51.96% and a net present value of RMB 904,582,400, with an anticipated annual revenue of RMB 1,970,283,200 once operational [4]. - The "R&D Center Construction and New Drug Development" project aims to enhance the company's R&D capabilities, although direct economic benefits cannot be quantified at this stage due to the nature of drug development processes [4]. Financial Summary - The total amount of funds raised was RMB 599,669,492.10, with cumulative usage amounting to RMB 399,868,000, indicating a significant portion of the funds has been allocated to various projects [3][4]. - The company has approved the permanent allocation of surplus funds to supplement working capital, reflecting a strategic financial management approach [2][3].
富煌钢构: 前次募集资金使用情况鉴证报告
Zheng Quan Zhi Xing· 2025-05-26 15:16
Group 1 - The report provides a verification of the use of previously raised funds by Anhui Fuhuang Steel Structure Co., Ltd. as of December 31, 2024 [1][2] - The management is responsible for ensuring the accuracy and completeness of the information provided in the report [1][2] - The report confirms that the previously raised funds were used in accordance with the regulations set by the China Securities Regulatory Commission [2][3] Group 2 - The company raised a total of RMB 655 million through a non-public offering of 98.9426 million shares at a price of RMB 6.62 per share, with net proceeds amounting to RMB 640.4371 million after deducting fees [3][4] - As of December 31, 2024, the total amount of previously raised funds held in the bank account was RMB 640.4371 million [5][6] - There were no changes to the previously raised funds, and the actual investment amount did not differ significantly from the committed investment amount [6]